...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Clinical application of determining serum AFP-IgM complexes for diagnosis of small hepatocellular carcinoma.
【24h】

Clinical application of determining serum AFP-IgM complexes for diagnosis of small hepatocellular carcinoma.

机译：测定血清AFP-IgM复合物在小肝细胞癌诊断中的临床应用。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Diagnosis of primary hepatocellular carcinoma (HCC) at early stages has obviously been improved since determination of serum levels of free alpha-fetoprotein (AFP) was implemented. AFP has been considered as the standard tumor marker of primary HCC, although certain patients have very low serum free AFP levels. In the present study, clinical application of measuring serum AFP-IgM immune complexes compared to the serum free AFP was evaluated for diagnosis of small HCC. One hundred and three healthy controls, 74 patients with primary HCC, 27 patients with liver cirrhosis and 63 patients with chronic hepatitis were included in the present study. Serum levels of AFP-IgM immune complexes and free AFP were determined by ELISA and electrochemiluminescence, respectively. The best cut-off values of AFP-IgM immune complexes and free AFP for the diagnosis of primary HCC were 300 AU/ml and 10 mug/l, respectively, according to the area under the curve (AUC). At these cut-off values, the sensitivities of AFP-IgM and AFP for HCC were 64.9% and 79.7%, respectively, with specificities of 75.6% and 80.3%, respectively. Combining positivity for both tumor markers, the specificity and accuracy of diagnosis of HCC were 89.1% and 79.0%, respectively. Moreover, when the diameter of the tumor was 0.05). The ROC area was significantly different between AFP-IgM and AFP (Z = 2.19, p = 0.0286). In addition, the serum AFP-IgM levels were significantly higher in the patients with tumor diameter 3 cm (604.9 +/- 749.9 AU/ml). It is concluded that determining serum levels of both AFP-IgM immune complex and AFP may have potential benefit for the diagnosis of small HCC.
机译：自从实施血清游离甲胎蛋白（AFP）血清水平测定以来，早期原发性肝细胞癌（HCC）的诊断已明显改善。尽管某些患者的无血清AFP水平非常低，但AFP被认为是原发性HCC的标准肿瘤标志物。在本研究中，评估了与无血清AFP相比测量血清AFP-IgM免疫复合物的临床应用，以诊断小肝癌。本研究纳入了一百零三名健康对照者，74例原发性肝癌患者，27例肝硬化患者和63例慢性肝炎患者。分别通过ELISA和电化学发光测定血清AFP-IgM免疫复合物和游离AFP的水平。根据曲线下面积（AUC），用于诊断原发性肝癌的AFP-IgM免疫复合物和游离AFP的最佳临界值分别为300 AU / ml和10马克/升。在这些临界值下，AFP-IgM和AFP对HCC的敏感性分别为64.9％和79.7％，特异性分别为75.6％和80.3％。结合两种肿瘤标志物的阳性率，HCC诊断的特异性和准确性分别为89.1％和79.0％。此外，当肿瘤直径为≤3 cm（被认为是小肝癌）时，敏感性和特异性分别为100.0％和75.3％。 AFP-IgM水平，患者性别或年龄之间无显着相关性（p> 0.05）。 AFP-IgM和AFP之间的ROC区域显着不同（Z = 2.19，p = 0.0286）。此外，肿瘤直径≤3 cm（1090.4 +/- 571.8 AU / ml）的患者的血清AFP-IgM水平明显高于肿瘤直径≥3 cm（604.9 +/- 749.9 AU）的患者/ ml）。结论是，同时测定AFP-IgM免疫复合物和AFP的血清水平可能对诊断小肝癌具有潜在的益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号